+ Watch DRRX
on My Watchlist
The Company is a pharmaceutical Company developing therapies for the treatment of chronic diseases and conditions with its proprietary drug formulations and delivery platform technologies.
Durect has several products in phase II trials that will really be excellent for the treament of post operative pain. Striker, a company that would compete with Durect just purchased something like 18,000,000$ worth of shares of durect. They must think that the new delivery system that durect is making is going to do well. Also, check out the other products that they are developing. They are really great products.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions